Read this before relying on disease or FDA content
This notice explains the limits of the website’s investigational, clinical-registry, regulatory, and professional-services content.
Last reviewed: August 16, 2026
Investigational content
COPD, systemic lupus erythematosus, and kidney-injury content describes areas of research and development. It does not state or imply that any product is proven safe or effective, available for treatment, cleared for a clinical study, or approved for marketing.
ClinicalTrials.gov
A study’s presence on ClinicalTrials.gov does not mean the U.S. government reviewed the study, determined that it is safe or scientifically valid, or approved the intervention. Study status may change after this website is reviewed.
IND and FDA language
An IND submission is not FDA approval. An IND that is in effect permits a specified investigation to proceed under applicable requirements; it does not authorize commercial marketing or establish safety or effectiveness. A BLA and FDA licensure are separate later milestones for a specific product and indication.
Professional scope
Website descriptions are general capabilities, not a project proposal, contract, regulatory opinion, legal advice, medical advice, statistical analysis, quality certification, or guarantee of outcome. A project scope must identify the responsible sponsor, applicant, manufacturer, laboratory, clinical parties, and qualified advisers.
No patient services or recruitment
This website does not offer treatment, diagnose disease, recommend an intervention, evaluate patient eligibility, enroll participants, or replace a licensed clinician or an authorized clinical-research team.
Sensitive information
Do not send patient information, protected health information, medical records, trade secrets, unpublished protocols, confidential CMC data, credentials, or controlled documents through the website form. Use an approved confidential exchange process after the parties define the engagement.
Current sources
- FDA — Investigational New Drug (IND) Application
- FDA — Approved Cellular and Gene Therapy Products
- FDA — Therapeutic Biologics Applications (BLA)
- ClinicalTrials.gov
Because regulatory and clinical information changes, verify the current official record before relying on any status statement.